Trussed in Evidence? Ambiguities at the Interface between Clinical Evidence and Clinical Practice

Transcultural Psychiatry

Volumn 46, Issue 1, 2009, Pages 16-37

  Healy, David ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

guideline capture; informational reductionism; rating scale mongering; treatment effects

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; IMIPRAMINE; LITHIUM; METHYLPHENIDATE; MOOD STABILIZER; NEUROLEPTIC AGENT; NICOTINE; OLANZAPINE; PLACEBO; PSYCHOTROPIC AGENT; RESERPINE; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

AKATHISIA; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DEPRESSION; DRUG EFFICACY; DRUG INDUSTRY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; INFORMATION PROCESSING; MANIA; MEDICAL DECISION MAKING; MENTAL HEALTH CARE; MOOD DISORDER; OUTCOME ASSESSMENT; PATENT; PHYSICIAN ATTITUDE; PLACEBO EFFECT; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PSYCHIATRY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

BIAS (EPIDEMIOLOGY); EVIDENCE-BASED MEDICINE; HUMANS; MENTAL DISORDERS; PRACTICE GUIDELINES AS TOPIC; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 63049132562     PISSN: 13634615     EISSN: None     Source Type: Journal    
DOI: 10.1177/1363461509102285     Document Type: Article

References (54)

1. Abraham, J. (2002). The pharmaceutical industry as political player. Lancet, 360(9344), 1498-1502.
2. Abraham, J., & Reed, T. (2002). Progress, innovation and regulatory science in drug development: The politics of international standard setting. Social Studies of Science, 32(2), 1-33.
3. Berenson, A. (2007, January 5). Lilly settles with 18,000 over Zyprexa. New York Times.
4. Bisson, J.L., Jenkins, P.L., Alexander, J., & Bannister, C. (1997). Randomised controlled trial of psychological debriefing for victims of acute burn trauma. British Journal of Psychiatry, 171, 78-81.
5. Cade, J.F.J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 2(10), 349-353.
6. Colbrook, P. (2005, April 9). Can you ignore guidelines? British Medical Journal Careers, 143-144.
7. Colton, C.W., & Manderscheid, R.W. (2006). Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Preventing Chronic Disease, 3(2). Retrieved from http://www.cdc.gov/pcd/issues/2006/apr/05_0180.htm.
8. Croudace, T., Evans, J., Harrison, G., Sharp, D.J., Wilkinson, E., McCann, G., Spence, M., Crilly, C., & Brindle, L. (2003). Impact of the ICD-10 primary health care (PHC) diagnostic and management guidelines for mental disorders on detection and outcome in primary care: Cluster randomized controlled trial. British Journal of Psychiatry, 182, 20-30.
9. Davies, D.L., & Shepherd, M. (1955). Reserpine in the treatment of anxious and depressed patients. Lancet, 269(6881), 117-121.
10. Delay, J., & Deniker, P. (1952). 38 cas de psychoses traitées par la cure prolongée et continue de 4560 RP. Compte Rendu du Congrès Aliénistes et Neurologistes de Langue Francaise, 50, 497-502.
11. Delay, J., Deniker, P., & Ropert, R. (1955). Étude de 300 dossiers de maladies psychotiques traits par la chlorpromazine en service fermé depuis 1952. L'Encéphale, 528-535.
12. Evarts, E. (1959). A discussion of the relevance of effects of drugs on animal behavior to the possible effects of drugs on psychopathological processes in man. In J. O. Cole & R. W. Gerard (Eds.), Psychopharmacology: Problems in evaluation (pp. 284–306). Washington, DC: National Academy of Sciences/National Research Council Publication 583.
13. Fish, F. (1964). The influence of the tranquilizers on the Leonhard schizophrenic syndromes. L'Encéphale, 53, 245-249.
14. Ghaemi, N.S. (2005). Uses and abuses of evidence based medicine in psychiatry. In Evidence based psychiatry: What it is and what it is not. American Psychiatric Association meeting, Atlanta Symposium 37A, May. Retrieved from http://www.psych.org/edu/other_res/lib_archives/archives/meetings/2005saps.cfm; http://www.mobiltape.com.
15. Harris, J. (2005). The increased diagnosis of juvenile ‘bipolar disorder,’ what are we treating? Psychiatric Services 56, 529-531.
16. Healy, D. (1997). The antidepressant era. Cambridge, MA: Harvard University Press.
17. Healy, D. (2004). Let them eat prozac. New York: New York University Press.
18. Healy, D. (2006a). The antidepressant tale: Figures signifying nothing? Advances in Psychiatric Treatment, 12, 320-328.
19. Healy, D. (2006b). Did regulators fail over selective serotonin reuptake inhibitors. British Medical Journal, 333, 92-95.
20. Healy, D. (2006c). The latest mania. Selling bipolar disorder. PloS Medicine, 3(4). Retrieved from http://dx.doi.org/10.1371/journal.pmed.0030185.
21. Healy, D. (2006d). Manufacturing consensus. Culture, Medicine and Psychiatry, 30(2), 135-156. DOI: 10.1007/s11013-006-9013-3.
22. Healy, D., & Cattell, D. (2003). The Interface between authorship, industry and science in the domain of therapeutics. British Journal of Psychiatry, 182, 22-27.
23. Healy, D., Harris, M., Tranter, R., Gutting, P., Austin, R., Jones-Edwards, G., & Roberts, A.P. (2006). Lifetime suicide rates in treated schizophrenia: 1875-1924 and 1994-1998 cohorts compared. British Journal of Psychiatry, 188, 223-228.
24. Healy, D., & Le Noury, J. (2007). Pediatric bipolar disorder. An object of study in the creation of an illness. The International Journal of Risk & Safety in Medicine, 19, 209-221.
25. Healy, D., & Nutt, D. (1997). British Association for Psychopharmacology consensus on statement on childhood and learning disabilities psychopharmacology. Journal of Psychopharmacology, 11, 291-294.
26. Healy, D., & Savage, M. (1998). Reserpine exhumed. British Journal of Psychiatry, 172, 376-378.
27. Healy, D., Savage, M., Michael, P., Harris, M., Hirst, D., Carter, M., Cattell, D., McMonagle, T., Sohler, N., & Susser, E. (2001). Psychiatric bed utilisation: 1896 and 1996 compared. Psychological Medicine, 31(5), 779-790.
28. Jones, P.B., Barnes, T.R., Davies, L., Dunn, G., Lloyd, H., Hayhurst, K.P., Murray, R.M., Marwick, A., & Lewis, S.W. (2006). Randomized controlled trial of the effect on quality of life of second vs first generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry, 63, 1079-1087.
29. Joukamaa, M.J., Heliovaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. British Journal of Psychiatry, 188, 122-127.
30. Khanna, S., Vieta, E., Lyons, B., Eerdekens, M., & Kramer, M. (2005). Risperidone in the treatment of acute mania: Double-blind, placebo-controlled study. British Journal of Psychiatry, 187, 229-234.
31. Kirsch, I., Moore, T.J., Scoboria, A., & Nicholls, S.S. (2002). The Emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention and Treatment. Retrieved from http://www.journals.apa.org/prevention/volume5/pre0050023a.html.
32. Kirsch, I., & Sapirstein, G. (1998). Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication. Prevention and Treatment, 1. Retrieved from http://www.journals.apa.org/prevention/volume1/pre0010002a.html.
33. Kuhn, R. (1958). The treatment of depressive states with G22355 (imipramine hydrochloride). American Journal of Psychiatry, 115(5), 455-464.
34. Lemmens, T., & Freedman, B. (2000). Ethics review for sale? Conflict of interest and commercial research review boards. The Milbank Quarterly, 78(4), 547-584.
35. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., & Hsiao, J.K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
36. Marshall, B. (2002). Helicobacter pioneers. Firsthand accounts from the scientists who discovered helicobacters, 1892-1982. Victoria, Australia: Blackwell Science.
37. National Institute for Clinical Excellence. (NICE). (2005). Post-traumatic stress disorder. Clinical Guideline, 26. Retrieved from http://www.nice.org.uk.
38. National Institute for Health & Clinical Excellence. (NICE). (2006). Bipolar disorder. Clinical Guideline, 38. Retrieved from http://www.nice.org.uk.
39. National Institute for Health & Clinical Excellence. (NICE). (2007). Antenatal and postnatal mental health. Clinical Guideline, 45. Retrieved from http://www.nice.org.uk.
40. Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000). Time trends in schizophrenia mortality in Stockholm County, Sweden: A cohort study. British Medical Journal, 321, 483-484.
41. Petryna, A. (2006). Globalizing human subjects’ research. In A. Petryna, A. Lakoff, & A. Kleinman (Eds.), Global pharmaceuticals: Ethics, markets, practices (pp. 33–60). Durham, NC: Duke University Press.
42. Porter, T. (1996). Trust in numbers: The pursuit of objectivity in science and public life. Princeton, NJ: Princeton University Press.
43. Raphael, B., Meldrum, L., & McFarlane, A.C. (1995). Does debriefing after psychological trauma work? Time for randomised controlled trials. British Medical Journal, 310, 1479-1480.
44. Robertson, M.M., & Trimble, M. (1982). Major tranquilizers used as antidepressants. Journal of Affective Disorders, 4, 173-193.
45. Shepherd, M. (1998). Psychopharmacology: Specific and non-specific. In D. Healy (Ed.), The psychopharmacologists, Volume 2 (pp. 237–257). London: Arnold.
46. Smirk, F.H., & McQueen, E.G. (1955). Comparison of rescinamine and reserpine as hypotensive agents. Lancet, 115-116.
47. Smith, G.C., & Pell, J.P. (2003). Parachute use to prevent death and major trauma related to gravitational challenge. British Medical Journal, 327, 1459-1461.
48. Srinivasan, S., Pai, S.A., Bhan, A., Jesani, A., & Thomas, G. (2006). Trial of risperidone in India - concerns. British Journal of Psychiatry, 188, 489-492.
49. Stone, M., & Jones, L. (2006). Clinical review: Relationship between antidepressant drugs and adult suicidality. Retrieved from http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm, p 31.
50. Storosum, J.G., Wohlfarth, T., Gispen-de Wied, C.C., Linszen, D.H., Gersons, B.P.R., van Zwieten, B.J., & van den Brink, W. (2005). Suicide-risk in placebo controlled trials of treatment for acute manic episode and prevention of manic-depressive episode. American Journal of Psychiatry, 162, 799-802.
51. Teicher, M.H., Glod, C., & Cole, J.O. (1990). Emergence of intense suicidal preoccupation during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
52. Tohen, M., Calabrese, J.R., Sachs, G.S., Banov, M.D., Detke, H.C., Risser, R., Baker, R.W., Chou, J.C. -Y., & Bowden, C.L. (2006). Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. American Journal of Psychiatry, 163, 247-256.
53. Tyrer, P., King, M., & Fluxman, J. (2003). Treatment of common mental disorders in general practice: Are current guidelines useless? British Journal of Psychiatry, 183, 78.
54. Wallace, D.C. (1955). Treatment of hypertension: Hypotensive drugs and mental changes. Lancet, 269(6881): 116-117.